Skip to content

INTELLIPHARMACEUTICS INTERNATIONAL INC.: 20-F/A filed 2022-05-09

What INTELLIPHARMACEUTICS INTERNATIONAL INC. reported in its annual report amendment (foreign private issuer) filed 2022-05-09 (fiscal FY 2021): 38 published measures, 97 facts as tagged in accession 0001654954-22-006198.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
20-F/A (annual report amendment (foreign private issuer))
Filed
2022-05-09
Fiscal period
fiscal FY 2021
Accession
0001654954-22-006198 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INTELLIPHARMACEUTICS INTERNATIONAL INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-11-302,096,425USD
At 2020-11-303,387,055USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-11-3010,251,643USD
At 2020-11-309,700,644USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-11-30-8,155,218USD
At 2020-11-30-6,313,589USD
At 2019-11-30-3,692,221USD
At 2018-11-304,102,307USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-11-30771,945USD
At 2020-11-30202,046USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-12-01 to 2021-11-30-5,145,155USD365
2019-12-01 to 2020-11-30-3,390,965USD366
2018-12-01 to 2019-11-30-8,084,646USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-12-01 to 2021-11-30-2,461,329USD365
2019-12-01 to 2020-11-30112,108USD366
2018-12-01 to 2019-11-30-6,663,677USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-12-01 to 2021-11-300USD365
2019-12-01 to 2020-11-303,875USD366
2018-12-01 to 2019-11-3014,474USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-12-01 to 2021-11-300USD365
2019-12-01 to 2020-11-301,401,517USD366
2018-12-01 to 2019-11-303,480,516USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-12-01 to 2021-11-303,031,228USD365
2019-12-01 to 2020-11-300USD366
2018-12-01 to 2019-11-30100,896USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-12-01 to 2021-11-300USD365
2019-12-01 to 2020-11-3025,316USD366
2018-12-01 to 2019-11-30-14,474USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-11-30-102,241,705USD
At 2020-11-30-97,096,550USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-12-01 to 2021-11-30-5,145,155USD365
2019-12-01 to 2020-11-303,390,965USD366
2018-12-01 to 2019-11-308,084,646USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-11-30994,109USD
At 2020-11-301,770,137USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-12-01 to 2021-11-3011,985USD365
2019-12-01 to 2020-11-3071,645USD366
2018-12-01 to 2019-11-30264,568USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-12-01 to 2021-11-30-4,173,076USD365
2019-12-01 to 2020-11-30-4,678,308USD366
2018-12-01 to 2019-11-30-7,834,950USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-11-301,102,316USD
At 2020-11-301,478,987USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-12-01 to 2021-11-30549,299USD365
2019-12-01 to 2020-11-30969,653USD366
2018-12-01 to 2019-11-30247,516USD365

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-11-303,779,550USD
At 2020-11-304,103,966USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-11-300USD
At 2020-11-30566,384USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-12-01 to 2021-11-304,173,076USD365
2019-12-01 to 2020-11-306,079,825USD366
2018-12-01 to 2019-11-3011,282,398USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-11-300USD
At 2020-11-30112,672USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-12-01 to 2021-11-300USD365
2019-12-01 to 2020-11-301,401,517USD366
2018-12-01 to 2019-11-303,447,448USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-12-01 to 2021-11-301,249,676USD365
2019-12-01 to 2020-11-302,147,432USD366
2018-12-01 to 2019-11-304,167,801USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-12-01 to 2021-11-302,661,875USD365
2019-12-01 to 2020-11-303,517,018USD366
2018-12-01 to 2019-11-306,608,794USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-11-3023,678,105shares
At 2020-11-3023,678,105shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-11-3044,626,436USD
At 2020-11-3044,354,138USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-11-30284,421USD
At 2020-11-30284,421USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-11-300USD
At 2020-11-30137,931USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-11-300USD
At 2020-11-30157,110USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-11-307,463,200USD
At 2020-11-307,977,702USD
At 2019-11-308,065,596USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-11-306,469,091USD
At 2020-11-306,207,565USD
At 2019-11-305,792,190USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-11-302,272,610USD
At 2020-11-301,780,272USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2021-11-3062,192USD
At 2020-11-30115,750USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-12-01 to 2021-11-30-5,259,342USD365
2019-12-01 to 2020-11-30-3,358,132USD366
2018-12-01 to 2019-11-30-8,090,010USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-12-01 to 2021-11-30261,525USD365
2019-12-01 to 2020-11-30415,375USD366
2018-12-01 to 2019-11-30506,685USD365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2020-12-01 to 2021-11-30169,552USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-12-01 to 2021-11-30566,384USD365
2019-12-01 to 2020-11-30-389,182USD366
2018-12-01 to 2019-11-3061,861USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-12-01 to 2021-11-300USD365
2019-12-01 to 2020-11-300USD366
2018-12-01 to 2019-11-30-97,480USD365

Inspect the source

Entity
INTELLIPHARMACEUTICS INTERNATIONAL INC. / CIK 0001474835
Captured
SEC response SHA-256
b43bbafa3486320e53e47da45874c043f53139ec0b74aaba3fa200c8a1927667

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001474835.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))